Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $107 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a $107 price target.
April 10, 2024 | 1:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Axsome Therapeutics and maintained a $107 price target.
The reiteration of an Overweight rating and the maintenance of a high price target ($107) by a reputable analyst like Charles Duncan from Cantor Fitzgerald could instill confidence among investors and potentially drive up the stock price of Axsome Therapeutics in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100